Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Behavioral Processes Underlying Reward Processing in Depression

This study has been completed.
Sponsor:
Collaborator:
Massachusetts General Hospital
Information provided by:
Affective Neuroscience Laboratory
ClinicalTrials.gov Identifier:
NCT00205933
First received: September 13, 2005
Last updated: December 4, 2007
Last verified: November 2007

September 13, 2005
December 4, 2007
April 2004
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00205933 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Behavioral Processes Underlying Reward Processing in Depression
Behavioral Processes Underlying Reward Processing in Depression

The purpose of this project is to use behavioral techniques to investigate emotional processing in subjects with major depression and healthy comparison subjects.

A promising strategy for parsing the heterogeneity of Major Depressive Disorder is to identify phenotypes characterized by reliable functional abnormalities. Anhedonia, the lack of reactivity to pleasurable stimuli, is considered a trait marker for depression. Using an objective behavioral task this project aims to investigate hedonic capacity in subjects meeting a DSM-IV diagnosis of Major Depressive Disorder.

Observational
Observational Model: Cohort
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Non-Probability Sample

Control participants, Participants with MDD, Participants with Bipolar Disorder

  • Major Depressive Disorder
  • Bipolar Disorder
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
78
June 2007
Not Provided

Inclusion Criteria:

Depressed participants:

  • Right-handed
  • DSM-IV diagnosis of MDD
  • Score of at least 17 on the 21-item HAM-D scale
  • Absence of any psychotropic medications for at least 2 weeks (6 months for dopaminergic drugs (including methylphenidate), 6 weeks for fluoxetine, and 4 weeks for neuroleptics and benzodiazepines because of longer half-lives.)
  • No current or past history of MDD with psychotic features
  • Absence of any other Axis I or Axis II diagnosis (Including bipolar disorder and current or lifetime history of alcohol or substance abuse or dependence.) Particularly, subjects with a history of alcoholism and substance abuse will be excluded, since dopaminergic alterations have been reported in these conditions. Exclusion of patients with comorbid Axis I or Axis II diagnoses will be necessary as evidence exists of alteration in dopamine receptor density in detached personality and social phobia. The alteration of dopamine in the brain may in turn alter behavior.
  • Absence of significant medical conditions
  • Absence of ECT in the previous 6 months
  • Ability to provide informed consent/authorization

Bipolar participants:

  • Both genders and all ethnic origins
  • Age between 18 and 64
  • Right-handed
  • DSM-IV diagnosis of Bipolar Disorder I or II
  • Score of at least 17 on the 21-item Hamilton Depression Rating Scale (HAM-D)
  • Absence of any psychotropic medications for at least 2 weeks (6 months for dopaminergic drugs (including methylphenidate), 6 weeks for fluoxetine, and 4 weeks for neuroleptics and benzodiazepines because of longer half-lives.)
  • No current or past history of MDD with psychotic features
  • Absence of any other Axis I or Axis II diagnosis (Including current or lifetime history of alcohol or substance abuse or dependence.) Particularly, subjects with a history of alcoholism and substance abuse will be excluded.
  • Absence of significant medical conditions
  • Absence of ECT in the previous 6 months
  • Ability to provide informed consent/authorization

Control Participants:

  • Right-handed
  • Absence of medical, neurological, and psychiatric illness (including alcohol and substance abuse), as assessed by the SCID
  • Absence of any medications for at least 2 weeks
  • Informed consent/authorization

Exclusion Criteria:

  • Left-handed/ambidextrous
  • Evidence of neurological illness
  • Current alcohol or substance abuse
  • Serious suicide or homicide risk
Both
18 Years to 64 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00205933
2003-P-000994
Yes
Diego Pizzagalli, Principal Investigator, Harvard University
Affective Neuroscience Laboratory
Massachusetts General Hospital
Principal Investigator: Diego A Pizzagalli, PhD Harvard University
Affective Neuroscience Laboratory
November 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP